Pharmaceuticals News

VERAXA Biotech presents first in vivo proof-of-concept for BiTAC®-ADC: tumor-selective activation with potent anti-tumor efficacy and improved safety.

Post-hoc Phase 2 data show greater bone mineral density (BMD) gains and anabolic effect with EB613 in postmenopausal women with baseline T-scores of ≤-2.5 (osteoporosis) versus T-scores of >-2.5...

Visara secures exclusive worldwide rights, excluding Greater China, from Wuhan Hiteck Biological Pharma to develop and commercialize HT006.2.2 Visara plans to develop HT006.2.2 as VIS-102, its second...

Opus Genetics to Present at the Chardan Annual Healthcare Conference

WALTHAM, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Sironax, a global clinical-stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory and immunologic,...

CANTANHEDE, Portugal, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a global leader in medical cannabis research, cultivation, production, products and distribution and a division of Tilray...

沃尔瑟姆，马萨诸塞州, Oct. 13, 2026 (GLOBE NEWSWIRE) --...

沃尔瑟姆，马萨诸塞州, Oct. 13, 2026 (GLOBE NEWSWIRE) --...

TRIV-573, potential first-in-class KLK5/7 x IL-13 bispecific, simultaneously targets skin barrier dysfunction and inflammation to address fundamental drivers of disease Company also announces the...

AHEAD-MERIT Phase 2/3 clinical trial did not meet its first dual primary endpoint of progression-free survival for the mRNA cancer immunotherapy candidate BNT113 plus pembrolizumab compared with...